Skip to main content
CNSX:HUGE

FSD Pharma News Headlines

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume4,870 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

FSD Pharma (CNSX HUGE) News Headlines Today

SourceHeadline
Proactive news headlines including Mirasol Resources, Milestone Scientific, Steppe Gold and Gold Resource CorpProactive news headlines including Mirasol Resources, Milestone Scientific, Steppe Gold and Gold Resource Corp
feeds.benzinga.com - May 17 at 3:31 PM
FSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial OfficerFSD Pharma Announces Filing of Criminal Complaint Against Former Chief Financial Officer
finance.yahoo.com - May 13 at 10:06 AM
Proactive news headlines including Numinus Wellness, Organic Garage, GoviEx Uranium, Ipsidy and Arcadia BiosciencesProactive news headlines including Numinus Wellness, Organic Garage, GoviEx Uranium, Ipsidy and Arcadia Biosciences
feeds.benzinga.com - May 10 at 3:24 PM
FSD Pharma Announces Appointment of Interim Chief Financial OfficerFSD Pharma Announces Appointment of Interim Chief Financial Officer
finance.yahoo.com - May 5 at 10:49 AM
Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders Meeting - Urge Shareholders to Vote Their Shares Using the Gold ProxyConcerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy
finance.yahoo.com - April 26 at 10:28 PM
FSD Pharma Files Proxy Materials and Sends Letter to ShareholdersFSD Pharma Files Proxy Materials and Sends Letter to Shareholders
finance.yahoo.com - April 23 at 9:46 AM
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder MeetingFSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
finance.yahoo.com - April 5 at 7:53 AM
Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving WednesdayWhy Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday
markets.businessinsider.com - March 17 at 2:09 PM
Stock Alert: FSD Pharma Gains 18% On License Agreement To Develop Vet DrugStock Alert: FSD Pharma Gains 18% On License Agreement To Develop Vet Drug
nasdaq.com - March 17 at 2:09 PM
Cofttek, Chinas Largest Manufacturer of PEA, Draws Attention of InvestorsCofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors
benzinga.com - February 13 at 1:21 PM
HUGE Nov 2020 7.500 callHUGE Nov 2020 7.500 call
ca.finance.yahoo.com - November 20 at 6:30 PM
FSD Pharma believes it has sufficient cash to complete Phase 2 coronavirus trialFSD Pharma believes it has sufficient cash to complete Phase 2 coronavirus trial
proactiveinvestors.com - November 13 at 10:45 PM
FSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patientsFSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patients
proactiveinvestors.com - November 4 at 10:17 PM
FSD Pharma Announces Settlement of Class Action ProceedingFSD Pharma Announces Settlement of Class Action Proceeding
finance.yahoo.com - October 29 at 8:39 AM
FSD Pharma suffers on $9.5M registered direct offeringFSD Pharma suffers on $9.5M registered direct offering
seekingalpha.com - October 16 at 8:31 AM
FSD Pharma launches mid-stage study of FSD201 in COVID-19; shares up 7%FSD Pharma launches mid-stage study of FSD201 in COVID-19; shares up 7%
seekingalpha.com - October 5 at 12:37 PM
FSD Pharma gets FDA approval to begin mid-stage testing of potential Covid-19 therapyFSD Pharma gets FDA approval to begin mid-stage testing of potential Covid-19 therapy
bizjournals.com - September 28 at 5:24 PM
BUZZ-U.S. STOCKS ON THE MOVE-Grid Dynamics, Centene Corp, Cal-Maine Foods, Inovio PharmaceuticalsBUZZ-U.S. STOCKS ON THE MOVE-Grid Dynamics, Centene Corp, Cal-Maine Foods, Inovio Pharmaceuticals
nasdaq.com - September 28 at 12:24 PM
FSD Pharma on go with mid-stage COVID-19 study with FSD201FSD Pharma on go with mid-stage COVID-19 study with FSD201
seekingalpha.com - September 28 at 12:24 PM
FSD Pharma, Inc.: FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 PatientsFSD Pharma, Inc.: FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
finanznachrichten.de - September 28 at 7:24 AM
FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 PatientsFSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
benzinga.com - September 28 at 7:24 AM
FSD Pharma higher on FDA approval of phase 2 clinical trial of FSD201FSD Pharma higher on FDA approval of phase 2 clinical trial of FSD201
seekingalpha.com - September 28 at 7:24 AM
FSD Pharma Inc. Class BFSD Pharma Inc. Class B
realmoney.thestreet.com - August 22 at 7:39 AM
HUGE.CN: FSD Pharma’s FSD’s Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA.HUGE.CN: FSD Pharma’s FSD’s Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA.
finance.yahoo.com - August 20 at 2:13 PM
FSD Pharma says $10M in new capital is gratifying as the firm makes progress in coronavirus trialFSD Pharma says $10M in new capital is 'gratifying' as the firm makes progress in coronavirus trial
proactiveinvestors.com - August 10 at 10:47 PM
FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional InvestorsFSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors
finance.yahoo.com - August 8 at 12:31 AM
FSD Pharma, Inc.: FSD Pharma Reports Second Quarter 2020 Financial ResultsFSD Pharma, Inc.: FSD Pharma Reports Second Quarter 2020 Financial Results
finanznachrichten.de - August 7 at 7:31 PM
FSD Pharma Reports Second Quarter 2020 Financial ResultsFSD Pharma Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 7 at 7:31 PM
FSD Pharma, Inc.: FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional InvestorsFSD Pharma, Inc.: FSD Pharma Inc. Announces Closing of US $10 Million Registered Direct Offering to Institutional Investors
finanznachrichten.de - August 6 at 6:26 PM
FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional InvestorsFSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors
finance.yahoo.com - August 6 at 6:26 PM
FSD Pharma announces US$10 million registered direct offering as it advances FSD201 as possible COVID-19 treatmentFSD Pharma announces US$10 million registered direct offering as it advances FSD201 as possible COVID-19 treatment
www.proactiveinvestors.com - July 31 at 6:16 PM
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip VideoFSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video
finance.yahoo.com - July 31 at 6:16 PM
FSD Pharma, Inc.: FSD Pharma Inc. Announces US$10 Million Registered Direct OfferingFSD Pharma, Inc.: FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
www.finanznachrichten.de - July 31 at 1:16 PM
FSD Pharma under pressure on $10M registered direct offeringFSD Pharma under pressure on $10M registered direct offering
seekingalpha.com - July 31 at 1:16 PM
FSD Pharma Inc. Announces US$10 Million Registered Direct OfferingFSD Pharma Inc. Announces US$10 Million Registered Direct Offering
finance.yahoo.com - July 31 at 1:16 PM
FSD Pharma notifies Health Canada it will forfeit licenses of subsidiary FV Pharma and suspend operationsFSD Pharma notifies Health Canada it will forfeit licenses of subsidiary FV Pharma and suspend operations
www.proactiveinvestors.com - July 30 at 7:58 PM
FSD Pharma’s medical marijuana dreams go up in smokeFSD Pharma’s medical marijuana dreams go up in smoke
www.msn.com - July 30 at 7:58 PM
FSD PharmaFSD Pharma
www.benzinga.com - July 30 at 7:58 PM
FSD Pharma, Inc.: FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.FSD Pharma, Inc.: FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.
www.finanznachrichten.de - July 30 at 9:57 AM
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologics Blowout QuarterThe Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
www.msn.com - July 30 at 9:57 AM
FSD Pharma exits cannabis, pivots to COVID-19FSD Pharma exits cannabis, pivots to COVID-19
seekingalpha.com - July 30 at 9:57 AM
FSD Pharma, Inc.: FSD Pharma Announces US$20M At-The-Market OfferingFSD Pharma, Inc.: FSD Pharma Announces US$20M At-The-Market Offering
www.finanznachrichten.de - July 13 at 7:50 AM
FSD Pharma launches $20M at-the-market offeringFSD Pharma launches $20M at-the-market offering
seekingalpha.com - July 13 at 7:50 AM
InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.comInvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com
finance.yahoo.com - June 23 at 12:55 PM
FSD Pharma, Inc.: FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEAFSD Pharma, Inc.: FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA
www.finanznachrichten.de - June 22 at 10:00 AM
FSD Pharma says Phase 1 study finds micro-PEA "safe and well tolerated"FSD Pharma says Phase 1 study finds micro-PEA "safe and well tolerated"
www.proactiveinvestors.com - June 22 at 10:00 AM
FSD Pharma +34% on favorable results from in-human study of FSD201FSD Pharma +34% on favorable results from in-human study of FSD201
seekingalpha.com - June 22 at 10:00 AM
FSD Pharma raises more than C$10M in private placement, makes progress with coronavirus treatmentFSD Pharma raises more than C$10M in private placement, makes progress with coronavirus treatment
www.proactiveinvestors.com - June 12 at 6:37 PM
HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patientsHUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients
finance.yahoo.com - June 9 at 12:44 PM
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional InvestorsFSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
finance.yahoo.com - June 9 at 12:44 PM
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.